The document outlines the proposed requirements for Stage 2 of Meaningful Use, including:
- Eligible professionals must meet or qualify for an exclusion to 17 core and 3 of 5 menu objectives, while hospitals must meet 16 core and 2 of 4 menu objectives. Both must report more clinical quality measures.
- Objectives involve increased percentages for items like CPOE, clinical decision support, recording patient data as structured data, and engaging patients online.
- It also discusses quality measure reporting requirements and considerations for both professionals and hospitals.
The Meaningful Use Stage 2 requirements include meeting or qualifying for exclusions to more objectives across core and menu sets compared to Stage 1. Eligible professionals must meet 17 core objectives and 5 menu objectives, while hospitals must meet 16 core and 2 menu objectives. Both must also report more clinical quality measures. The requirements focus on improving care coordination, patient engagement, population health, and privacy/security protections.
The document discusses the objectives and requirements of Meaningful Use (MU), an incentive program that promotes the adoption and meaningful use of electronic health records (EHRs). It outlines the core objectives that eligible professionals and hospitals must meet, such as computerized provider order entry, maintaining active medication lists, and exchanging key clinical information. The document also details the measure thresholds associated with each objective that providers must meet to qualify for MU incentive payments.
Meaningful Use Workgroup Recommendations Brian Ahier
The document summarizes the recommendations of the Meaningful Use Workgroup to the HIT Policy Committee regarding the objectives for Stage 2 of Meaningful Use. The Workgroup aligned the objectives with national healthcare priorities and recommended raising thresholds or expanding criteria for many Stage 1 objectives. They also proposed maintaining the current timeline but allowing a 90-day reporting period for providers to address concerns about implementation feasibility.
This document provides an overview of the requirements for achieving Meaningful Use under the Medicare and Medicaid EHR Incentive Programs. It defines Meaningful Use as using certified EHR technology to improve quality, safety, efficiency and health outcomes. The three main components of Meaningful Use are use of EHRs in a meaningful manner, electronic exchange of health information, and submission of clinical quality measures. Stage 1 requirements include completing core and menu set objectives related to EHR usage, engaging patients, care coordination, and privacy/security. Eligible professionals must meet 15 core objectives and hospitals must meet 14.
Hemovigilance is a continuous process of monitoring blood transfusions to collect data on adverse reactions, investigate their causes, and prevent future occurrences. India launched a national Hemovigilance program in 2012 to address issues with adverse reactions from blood transfusions. The program collects reports from medical colleges on transfusion reactions and assesses causality to advise regulators on safety and provide recommendations to stakeholders. It aims to improve transfusion safety and prevent adverse events.
The document discusses Materiovigilance, which is the monitoring of incidents involving medical devices. It aims to study device-related incidents, enable dangerous devices to be removed from the market, and improve device quality and safety for patients. The Materiovigilance Programme of India was established in 2015 after incidents involving malfunctioning medical devices caused patient deaths. It oversees monitoring centers that collect adverse event reports which are analyzed to detect safety issues and support regulatory decision-making regarding medical devices in India.
This document provides an overview and summary of changes between the proposed rule and final rule for implementing the Medicare and Medicaid EHR Incentive Program under the HITECH Act. Some key changes included modifications to the meaningful use criteria and clinical quality measures, clarification of provider eligibility requirements, and adjustment of measure thresholds. The final rule aimed to address concerns raised in public comments to better achieve the goals of improved care, health outcomes, and interoperability.
What you need to know about the Pharmacovigilance guidelines for companies marketing drugs in India. A concise overview of the six modules in the Guidance Document and the responsibilities of the Marketing Authorization Holders.
The Meaningful Use Stage 2 requirements include meeting or qualifying for exclusions to more objectives across core and menu sets compared to Stage 1. Eligible professionals must meet 17 core objectives and 5 menu objectives, while hospitals must meet 16 core and 2 menu objectives. Both must also report more clinical quality measures. The requirements focus on improving care coordination, patient engagement, population health, and privacy/security protections.
The document discusses the objectives and requirements of Meaningful Use (MU), an incentive program that promotes the adoption and meaningful use of electronic health records (EHRs). It outlines the core objectives that eligible professionals and hospitals must meet, such as computerized provider order entry, maintaining active medication lists, and exchanging key clinical information. The document also details the measure thresholds associated with each objective that providers must meet to qualify for MU incentive payments.
Meaningful Use Workgroup Recommendations Brian Ahier
The document summarizes the recommendations of the Meaningful Use Workgroup to the HIT Policy Committee regarding the objectives for Stage 2 of Meaningful Use. The Workgroup aligned the objectives with national healthcare priorities and recommended raising thresholds or expanding criteria for many Stage 1 objectives. They also proposed maintaining the current timeline but allowing a 90-day reporting period for providers to address concerns about implementation feasibility.
This document provides an overview of the requirements for achieving Meaningful Use under the Medicare and Medicaid EHR Incentive Programs. It defines Meaningful Use as using certified EHR technology to improve quality, safety, efficiency and health outcomes. The three main components of Meaningful Use are use of EHRs in a meaningful manner, electronic exchange of health information, and submission of clinical quality measures. Stage 1 requirements include completing core and menu set objectives related to EHR usage, engaging patients, care coordination, and privacy/security. Eligible professionals must meet 15 core objectives and hospitals must meet 14.
Hemovigilance is a continuous process of monitoring blood transfusions to collect data on adverse reactions, investigate their causes, and prevent future occurrences. India launched a national Hemovigilance program in 2012 to address issues with adverse reactions from blood transfusions. The program collects reports from medical colleges on transfusion reactions and assesses causality to advise regulators on safety and provide recommendations to stakeholders. It aims to improve transfusion safety and prevent adverse events.
The document discusses Materiovigilance, which is the monitoring of incidents involving medical devices. It aims to study device-related incidents, enable dangerous devices to be removed from the market, and improve device quality and safety for patients. The Materiovigilance Programme of India was established in 2015 after incidents involving malfunctioning medical devices caused patient deaths. It oversees monitoring centers that collect adverse event reports which are analyzed to detect safety issues and support regulatory decision-making regarding medical devices in India.
This document provides an overview and summary of changes between the proposed rule and final rule for implementing the Medicare and Medicaid EHR Incentive Program under the HITECH Act. Some key changes included modifications to the meaningful use criteria and clinical quality measures, clarification of provider eligibility requirements, and adjustment of measure thresholds. The final rule aimed to address concerns raised in public comments to better achieve the goals of improved care, health outcomes, and interoperability.
What you need to know about the Pharmacovigilance guidelines for companies marketing drugs in India. A concise overview of the six modules in the Guidance Document and the responsibilities of the Marketing Authorization Holders.
The document discusses changes between the proposed rule and final rule for implementing the Medicare and Medicaid EHR Incentive Program under the HITECH Act. Key changes included lowering the thresholds for meaningful use measures, modifying clinical quality measures, and clarifying eligible provider and hospital definitions. The final rule aimed to ease burden and address concerns raised during public comment period.
This document discusses pharmacovigilance (PV), which involves monitoring the safety of medicines. PV focuses on detecting adverse drug reactions through spontaneous reporting systems. Signal detection involves data mining to identify unexpected adverse reactions requiring further evaluation. Signals are strengthened by evaluating factors like case reports and biological plausibility. National PV centers play a key role by collecting reports, communicating signals to WHO databases, and taking necessary actions. The WHO PV program has grown from 10 countries in 1968 to over 130 currently.
Pharmacovigilance is the science of monitoring the effects of pharmaceutical products after they have been licensed for use, especially in order to identify and evaluate previously unreported adverse reactions. It aims to improve patient care and safety, public health, benefit-risk assessment of medicines, and understanding of pharmacovigilance. Similarly, materiovigilance monitors medical devices and hemovigilance monitors the blood transfusion system to protect patient safety. Adverse events following immunization (AEFI) surveillance also monitors vaccine safety. Together these systems aim to enhance safety across all medical treatments.
The document provides an introduction to materiovigilance and adverse event following immunization (AEFI) surveillance programs in India. It discusses the need for monitoring medical devices and vaccines for safety. It outlines the objectives and organizational structure of India's Materiovigilance Program of India and AEFI surveillance program. Key activities include reporting and investigating adverse events, analyzing data, and taking corrective actions. The roles of various stakeholders like monitoring centers, regulatory authorities, and hospitals are also summarized.
The Conference Board of Canada - Tuesday, April 11, 2017 - Toronto, ON
"Leveraging Change Leadership: Driving Innovation Procurement Forward"
Presentació a càrrec de Antoni Gilabert, director de l'àrea de Farmàcia i del Medicament del CSC
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012kamynevy
Pharmacovigilance in India has progressed significantly since the 1980s but still faces challenges due to the large population, many drug manufacturers, and lack of awareness and reporting. The Pharmacovigilance Programme of India was launched in 2010 to help ensure the benefits of medicines outweigh the risks. Areas for continued reform include increasing participation in international clinical trials, harmonizing guidelines with global practices, and improving adverse event reporting timelines. Industry, healthcare professionals, and the public all have important roles to play in ongoing pharmacovigilance efforts.
Setting up of new pharmacovigilance centresPriti Gupta
Cure & Care Pharma proposes establishing a Pharmacovigilance Centre to monitor drug safety. The centre would be approved by regulatory authorities and function to collect, analyze and communicate information about adverse drug reactions and risks. The proposal outlines the need for pharmacovigilance due to increasing drug availability and irrational practices. It describes the centre's scope, reporting processes, infrastructure needs and budget to effectively oversee post-marketing drug safety.
This document discusses Health Canada's Special Access Programme (SAP), which allows access to drugs that have not received market authorization for patients with serious or life-threatening conditions. The SAP received over 16,000 requests in 2015 to access about 500 drugs. While the SAP provides access to unapproved drugs that may help patients, it also has limitations compared to approved drugs due to limited safety and efficacy information. Health Canada aims to improve the SAP by transitioning some drugs to full market approval and making the application process more efficient.
OrHIMA Meaningful Use Stage 2 PresentationBrian Ahier
This document discusses changes from Stage 1 to Stage 2 of meaningful use for eligible professionals and hospitals. Key changes include increased objectives for clinical decision support, electronic prescribing, patient engagement and health information exchange. Stage 2 places more emphasis on care coordination through increased objectives for medication reconciliation, patient summaries and electronic transmission of health information between providers. The document also outlines new clinical quality reporting requirements and certification criteria for electronic health records.
Pharmacovigilance is the science of monitoring approved drugs to detect adverse effects. It aims to improve patient safety by understanding drug risks. Clinical trials cannot detect all risks due to limited size and duration. Spontaneous reporting allows healthcare providers to report suspected adverse drug reactions. Limitations of clinical data and withdrawals like thalidomide led to pharmacovigilance programs worldwide including the WHO program and national programs in India, UK, and US. Pharmacovigilance involves collecting, analyzing, and communicating safety information to improve patient therapy and public health.
Signifcance of pharmacovigilance & risk management planAnsuman Parida
Pharmacovigilance is concerned with monitoring the safety of pharmaceutical drugs. It involves collecting, detecting, and assessing adverse drug reactions and preventing harm to patients. A risk management plan describes the known safety risks of a drug and outlines activities to further characterize risks, minimize risks to patients, and evaluate the effectiveness of risk minimization measures. Key parties in a risk management plan include patients, healthcare professionals, regulators, payers, pharmaceutical companies, and politicians. Risk management plans help ensure medications are reasonably safe and effective for their intended uses.
Who expert committee recommendations for pharmaceutical productsswati2084
The document summarizes the 43rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. It discusses WHO's work with other international organizations to harmonize pharmaceutical standards and guidelines. It provides updates on ongoing initiatives to improve access to quality medicines, including for priority diseases and children. Key areas of focus are ensuring safety and efficacy of medicines through good manufacturing practices, international reference standards, prequalification programs, and combating counterfeit drugs.
This document discusses pharmacovigilance, which is the science of monitoring the safety of pharmaceutical drugs. It aims to improve patient safety, public health, assess risk and benefits of drugs, and promote effective communication. A functional pharmacovigilance system requires a national center, reporting system, database, advisory committee, and communication strategy. Any adverse drug reactions or lack of efficacy should be reported. Periodic safety update reports provide an evaluation of the risk-benefit balance of drugs and are submitted to regulatory authorities on defined timelines.
The document outlines the steps taken to implement a comprehensive transition of care program for patients with acute venous thromboembolic events (VTE) who present to the emergency department. The program allows for appropriately selected patients to be safely discharged directly from the ED to outpatient care with oral anticoagulation therapy. Key elements of the program include developing standardized order sets, patient education materials, and discharge processes, as well as establishing patient tracking and follow up. An evaluation of outcomes after one year found no patients experienced VTE-related readmissions or complications, and patient satisfaction with the program was high.
This document discusses the importance of pharmacovigilance, which is the science of monitoring the safety of pharmaceutical products. It defines pharmacovigilance and outlines its key aims such as improving patient safety and promoting rational drug use. The document then covers various topics related to pharmacovigilance including adverse event reporting, signal detection, risk management plans, and the assessment of the risk-benefit profiles of drugs. It emphasizes that pharmacovigilance is an ethical practice aimed at ensuring drugs cause less harm to patients.
Adverse drug reaction, pharmacovigilance, spontaneous ADR monitoring, Good Pharmacovigilance Practices, drug safety, patient safety, an overview of regulatory guidelines, medicine safety, medical regulations.
This document provides an overview of pharmacovigilance. It defines pharmacovigilance as the science relating to detection, assessment, understanding and prevention of adverse effects of medicines. The document outlines the aims, responsibilities and governing bodies of pharmacovigilance. It describes various methods used in pharmacovigilance including individual case safety reports, cohort event monitoring, and spontaneous reporting. It also discusses adverse drug reactions, signal detection, and terminology used in pharmacovigilance.
This document provides an overview of pharmacovigilance. It defines key terms like drug, adverse event, and pharmacovigilance. It describes the drug development process including preclinical and clinical trials. It explains the need for pharmacovigilance during clinical trials and after marketing to monitor for adverse events. It discusses how pharmacovigilance benefits public health and drug manufacturers by improving drug safety.
Stage 1 vs. Stage 2 Comparison Table for Eligible Hospit.docxwhitneyleman54422
Stage 1 vs. Stage 2
Comparison Table for Eligible
Hospitals and CAHs
Last Updated: August, 2012
1
•
•
•
•
•
•
•
•
•
•
•
•
CORE OBJECTIVES (16 total)
Stage 1
Objective
Stage 1 Measure Stage 2 Objective Stage 2 Measure
Use CPOE for
medication orders
directly entered by
any licensed
healthcare
professional who
can enter orders
into the medical
record per state,
local and
professional
guidelines
More than 30% of
unique patients with at
least one medication in
their medication list
admitted to the
eligible hospital’s or
CAH’s inpatient or
emergency
department (POS 21 or
23) have at least one
medication order
entered using CPOE
Use computerized
provider order entry
(CPOE) for medication,
laboratory and radiology
orders directly entered by
any licensed healthcare
professional who can
enter orders into the
medical record per state,
local and professional
guidelines
More than 60% of
medication, 30% of
laboratory, and 30% of
radiology orders created
by authorized providers of
the eligible hospital's or
CAH's inpatient or
emergency department
(POS 21 or 23) during the
EHR reporting period are
recorded using CPOE
Implement drug-
drug and drug-
allergy interaction
checks
The eligible
hospital/CAH has
enabled this
functionality for the
entire EHR reporting
period
No longer a separate
objective for Stage 2
This measure is
incorporated into the
Stage 2 Clinical Decision
Support measure
Record
demographics
Preferred
language
Gender
Race
Ethnicity
Date of birth
Date and
preliminary
cause of death
in the event of
mortality in the
eligible hospital
or CAH
More than 50% of all
unique patients
admitted to the
eligible hospital’s or
CAH’s inpatient or
emergency
department (POS 21 or
23) have demographics
recorded as structured
data
Record the following
demographics
Preferred
language
Gender
Race
Ethnicity
Date of birth
Date and
preliminary cause
of death in the
event of mortality
in the eligible
hospital or CAH
More than 80% of all
unique patients admitted
to the eligible hospital's or
CAH's inpatient or
emergency department
(POS 21 or 23) have
demographics recorded as
structured data
2
Maintain an up-to-
date problem list of
current and active
diagnoses
More than 80% of all
unique patients
admitted to the
eligible hospital’s or
CAH’s inpatient or
emergency
department (POS 21 or
23) have at least one
entry or an indication
that no problems are
known for the patient
recorded as structured
data
No longer a separate
objective for Stage 2
This measure is
incorporated into the
Stage 2 measure of
Summary of Care
Document at Transitions
of Care and Referrals
Maintain active
medication list
More than 80% of all
unique patients
admitted to the
eligible hospital’s or
CAH’s inpatient or
emergency
department (POS 21 or
23) have at least one
entry (or an indication
that the patie.
Eligible professionals and hospitals have core and menu objectives they must meet to achieve Stage 1 Meaningful Use of electronic health records. Objectives include items like electronic prescribing, clinical decision support, and exchanging key clinical information. Professionals must complete 20 objectives total and hospitals must complete 19. Both must report on clinical quality measures to CMS or states. The document provides details on Stage 1 Meaningful Use requirements and measures.
The document discusses changes between the proposed rule and final rule for implementing the Medicare and Medicaid EHR Incentive Program under the HITECH Act. Key changes included lowering the thresholds for meaningful use measures, modifying clinical quality measures, and clarifying eligible provider and hospital definitions. The final rule aimed to ease burden and address concerns raised during public comment period.
This document discusses pharmacovigilance (PV), which involves monitoring the safety of medicines. PV focuses on detecting adverse drug reactions through spontaneous reporting systems. Signal detection involves data mining to identify unexpected adverse reactions requiring further evaluation. Signals are strengthened by evaluating factors like case reports and biological plausibility. National PV centers play a key role by collecting reports, communicating signals to WHO databases, and taking necessary actions. The WHO PV program has grown from 10 countries in 1968 to over 130 currently.
Pharmacovigilance is the science of monitoring the effects of pharmaceutical products after they have been licensed for use, especially in order to identify and evaluate previously unreported adverse reactions. It aims to improve patient care and safety, public health, benefit-risk assessment of medicines, and understanding of pharmacovigilance. Similarly, materiovigilance monitors medical devices and hemovigilance monitors the blood transfusion system to protect patient safety. Adverse events following immunization (AEFI) surveillance also monitors vaccine safety. Together these systems aim to enhance safety across all medical treatments.
The document provides an introduction to materiovigilance and adverse event following immunization (AEFI) surveillance programs in India. It discusses the need for monitoring medical devices and vaccines for safety. It outlines the objectives and organizational structure of India's Materiovigilance Program of India and AEFI surveillance program. Key activities include reporting and investigating adverse events, analyzing data, and taking corrective actions. The roles of various stakeholders like monitoring centers, regulatory authorities, and hospitals are also summarized.
The Conference Board of Canada - Tuesday, April 11, 2017 - Toronto, ON
"Leveraging Change Leadership: Driving Innovation Procurement Forward"
Presentació a càrrec de Antoni Gilabert, director de l'àrea de Farmàcia i del Medicament del CSC
Pharmacovigilance in India -Dr. Kamlesh Patel for global bioclinical 2012kamynevy
Pharmacovigilance in India has progressed significantly since the 1980s but still faces challenges due to the large population, many drug manufacturers, and lack of awareness and reporting. The Pharmacovigilance Programme of India was launched in 2010 to help ensure the benefits of medicines outweigh the risks. Areas for continued reform include increasing participation in international clinical trials, harmonizing guidelines with global practices, and improving adverse event reporting timelines. Industry, healthcare professionals, and the public all have important roles to play in ongoing pharmacovigilance efforts.
Setting up of new pharmacovigilance centresPriti Gupta
Cure & Care Pharma proposes establishing a Pharmacovigilance Centre to monitor drug safety. The centre would be approved by regulatory authorities and function to collect, analyze and communicate information about adverse drug reactions and risks. The proposal outlines the need for pharmacovigilance due to increasing drug availability and irrational practices. It describes the centre's scope, reporting processes, infrastructure needs and budget to effectively oversee post-marketing drug safety.
This document discusses Health Canada's Special Access Programme (SAP), which allows access to drugs that have not received market authorization for patients with serious or life-threatening conditions. The SAP received over 16,000 requests in 2015 to access about 500 drugs. While the SAP provides access to unapproved drugs that may help patients, it also has limitations compared to approved drugs due to limited safety and efficacy information. Health Canada aims to improve the SAP by transitioning some drugs to full market approval and making the application process more efficient.
OrHIMA Meaningful Use Stage 2 PresentationBrian Ahier
This document discusses changes from Stage 1 to Stage 2 of meaningful use for eligible professionals and hospitals. Key changes include increased objectives for clinical decision support, electronic prescribing, patient engagement and health information exchange. Stage 2 places more emphasis on care coordination through increased objectives for medication reconciliation, patient summaries and electronic transmission of health information between providers. The document also outlines new clinical quality reporting requirements and certification criteria for electronic health records.
Pharmacovigilance is the science of monitoring approved drugs to detect adverse effects. It aims to improve patient safety by understanding drug risks. Clinical trials cannot detect all risks due to limited size and duration. Spontaneous reporting allows healthcare providers to report suspected adverse drug reactions. Limitations of clinical data and withdrawals like thalidomide led to pharmacovigilance programs worldwide including the WHO program and national programs in India, UK, and US. Pharmacovigilance involves collecting, analyzing, and communicating safety information to improve patient therapy and public health.
Signifcance of pharmacovigilance & risk management planAnsuman Parida
Pharmacovigilance is concerned with monitoring the safety of pharmaceutical drugs. It involves collecting, detecting, and assessing adverse drug reactions and preventing harm to patients. A risk management plan describes the known safety risks of a drug and outlines activities to further characterize risks, minimize risks to patients, and evaluate the effectiveness of risk minimization measures. Key parties in a risk management plan include patients, healthcare professionals, regulators, payers, pharmaceutical companies, and politicians. Risk management plans help ensure medications are reasonably safe and effective for their intended uses.
Who expert committee recommendations for pharmaceutical productsswati2084
The document summarizes the 43rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. It discusses WHO's work with other international organizations to harmonize pharmaceutical standards and guidelines. It provides updates on ongoing initiatives to improve access to quality medicines, including for priority diseases and children. Key areas of focus are ensuring safety and efficacy of medicines through good manufacturing practices, international reference standards, prequalification programs, and combating counterfeit drugs.
This document discusses pharmacovigilance, which is the science of monitoring the safety of pharmaceutical drugs. It aims to improve patient safety, public health, assess risk and benefits of drugs, and promote effective communication. A functional pharmacovigilance system requires a national center, reporting system, database, advisory committee, and communication strategy. Any adverse drug reactions or lack of efficacy should be reported. Periodic safety update reports provide an evaluation of the risk-benefit balance of drugs and are submitted to regulatory authorities on defined timelines.
The document outlines the steps taken to implement a comprehensive transition of care program for patients with acute venous thromboembolic events (VTE) who present to the emergency department. The program allows for appropriately selected patients to be safely discharged directly from the ED to outpatient care with oral anticoagulation therapy. Key elements of the program include developing standardized order sets, patient education materials, and discharge processes, as well as establishing patient tracking and follow up. An evaluation of outcomes after one year found no patients experienced VTE-related readmissions or complications, and patient satisfaction with the program was high.
This document discusses the importance of pharmacovigilance, which is the science of monitoring the safety of pharmaceutical products. It defines pharmacovigilance and outlines its key aims such as improving patient safety and promoting rational drug use. The document then covers various topics related to pharmacovigilance including adverse event reporting, signal detection, risk management plans, and the assessment of the risk-benefit profiles of drugs. It emphasizes that pharmacovigilance is an ethical practice aimed at ensuring drugs cause less harm to patients.
Adverse drug reaction, pharmacovigilance, spontaneous ADR monitoring, Good Pharmacovigilance Practices, drug safety, patient safety, an overview of regulatory guidelines, medicine safety, medical regulations.
This document provides an overview of pharmacovigilance. It defines pharmacovigilance as the science relating to detection, assessment, understanding and prevention of adverse effects of medicines. The document outlines the aims, responsibilities and governing bodies of pharmacovigilance. It describes various methods used in pharmacovigilance including individual case safety reports, cohort event monitoring, and spontaneous reporting. It also discusses adverse drug reactions, signal detection, and terminology used in pharmacovigilance.
This document provides an overview of pharmacovigilance. It defines key terms like drug, adverse event, and pharmacovigilance. It describes the drug development process including preclinical and clinical trials. It explains the need for pharmacovigilance during clinical trials and after marketing to monitor for adverse events. It discusses how pharmacovigilance benefits public health and drug manufacturers by improving drug safety.
Stage 1 vs. Stage 2 Comparison Table for Eligible Hospit.docxwhitneyleman54422
Stage 1 vs. Stage 2
Comparison Table for Eligible
Hospitals and CAHs
Last Updated: August, 2012
1
•
•
•
•
•
•
•
•
•
•
•
•
CORE OBJECTIVES (16 total)
Stage 1
Objective
Stage 1 Measure Stage 2 Objective Stage 2 Measure
Use CPOE for
medication orders
directly entered by
any licensed
healthcare
professional who
can enter orders
into the medical
record per state,
local and
professional
guidelines
More than 30% of
unique patients with at
least one medication in
their medication list
admitted to the
eligible hospital’s or
CAH’s inpatient or
emergency
department (POS 21 or
23) have at least one
medication order
entered using CPOE
Use computerized
provider order entry
(CPOE) for medication,
laboratory and radiology
orders directly entered by
any licensed healthcare
professional who can
enter orders into the
medical record per state,
local and professional
guidelines
More than 60% of
medication, 30% of
laboratory, and 30% of
radiology orders created
by authorized providers of
the eligible hospital's or
CAH's inpatient or
emergency department
(POS 21 or 23) during the
EHR reporting period are
recorded using CPOE
Implement drug-
drug and drug-
allergy interaction
checks
The eligible
hospital/CAH has
enabled this
functionality for the
entire EHR reporting
period
No longer a separate
objective for Stage 2
This measure is
incorporated into the
Stage 2 Clinical Decision
Support measure
Record
demographics
Preferred
language
Gender
Race
Ethnicity
Date of birth
Date and
preliminary
cause of death
in the event of
mortality in the
eligible hospital
or CAH
More than 50% of all
unique patients
admitted to the
eligible hospital’s or
CAH’s inpatient or
emergency
department (POS 21 or
23) have demographics
recorded as structured
data
Record the following
demographics
Preferred
language
Gender
Race
Ethnicity
Date of birth
Date and
preliminary cause
of death in the
event of mortality
in the eligible
hospital or CAH
More than 80% of all
unique patients admitted
to the eligible hospital's or
CAH's inpatient or
emergency department
(POS 21 or 23) have
demographics recorded as
structured data
2
Maintain an up-to-
date problem list of
current and active
diagnoses
More than 80% of all
unique patients
admitted to the
eligible hospital’s or
CAH’s inpatient or
emergency
department (POS 21 or
23) have at least one
entry or an indication
that no problems are
known for the patient
recorded as structured
data
No longer a separate
objective for Stage 2
This measure is
incorporated into the
Stage 2 measure of
Summary of Care
Document at Transitions
of Care and Referrals
Maintain active
medication list
More than 80% of all
unique patients
admitted to the
eligible hospital’s or
CAH’s inpatient or
emergency
department (POS 21 or
23) have at least one
entry (or an indication
that the patie.
Eligible professionals and hospitals have core and menu objectives they must meet to achieve Stage 1 Meaningful Use of electronic health records. Objectives include items like electronic prescribing, clinical decision support, and exchanging key clinical information. Professionals must complete 20 objectives total and hospitals must complete 19. Both must report on clinical quality measures to CMS or states. The document provides details on Stage 1 Meaningful Use requirements and measures.
The document summarizes changes to the Meaningful Use Stage 2 rules for electronic health record incentive programs. Key changes include allowing a 90-day reporting period in 2017 for first-time participants and those choosing to implement Stage 3 in 2017. It modifies measures related to patient engagement, public health reporting, and thresholds for Stage 3 objectives like computerized provider order entry and electronic prescribing. The final rule also changes the 2015 reporting period to 90 days and aligns future periods with the calendar year. It streamlines programs by removing redundant measures and modifies several objectives and measures for Stages 1, 2 and 3.
This document summarizes the requirements for achieving meaningful use of electronic health records (EHRs) in order to qualify for incentive payments under the HITECH Act. It outlines the core and menu set objectives that must be met in each reporting period, including recording patient demographics, maintaining problem lists and medication lists, incorporating lab results into the EHR, exchanging health information electronically between providers, and reporting clinical quality measures to CMS or states. It also describes the services that regional extension centers like the North Carolina AHEC can provide to help practices select, implement, and optimize the use of certified EHR systems to meet meaningful use standards.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
HIT Standards Committee Trudel CMS RulesBrian Ahier
The document discusses changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program. Key changes included clarifying provider eligibility, modifying clinical quality measures, and lowering thresholds for some meaningful use objectives. The final rule kept the same statutory requirements and meaningful use goals as the proposed rule.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures requirements for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting policies to fully implement the program in 2011.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures requirements for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting policies.
This document summarizes changes from the proposed rule to the final rule for Stage 1 of the Medicare and Medicaid EHR Incentive Program's meaningful use criteria. Key changes included lowering thresholds for some objectives, removing administrative transactions, adding new objectives, and modifying clinical quality measures for eligible professionals. The final rule provided more flexibility for states and clarified various eligibility and reporting requirements.
CoArtha Technolsolutions IT for Meaningful UseMapRecruit.com
CoArtha Technosolutions provides various healthcare IT services including electronic health record systems, healthcare portals, product development, and infrastructure management. The document discusses CoArtha's experience in healthcare domains, technologies used, and services offered to help healthcare providers achieve Meaningful Use of EHRs and qualify for related incentive payments under the HITECH Act.
2016 indicator reference guide viral load suppression at 12 months#GOMOJO, INC.
1) This indicator measures the percentage of ART patients with a viral load result documented within the past 12 months. Viral load testing is important for monitoring treatment effectiveness and preventing drug resistance.
2) The numerator is the number of ART patients (adults and children) with a viral load result documented in their medical record within the past 12 months. The denominator is the number of ART patients reviewed whose medical records were examined.
3) Achieving high rates of viral load testing is critical for monitoring treatment outcomes and scaling up HIV treatment programs. Support for viral load testing includes procurement of reagents, transportation of samples, and clinical mentoring at ART sites.
The document discusses the "meaningful use" regulation for electronic health records (EHRs) in the US. It notes that while EHRs can improve care, widespread adoption has been slow. The HITECH Act provides $27 billion over 10 years to encourage EHR adoption through Medicare and Medicaid incentive payments. To receive payments, providers must meet objectives for meaningful use of EHRs to advance care processes and outcomes. The regulation outlines a core set and menu set of objectives providers must achieve, such as maintaining up-to-date patient health information, engaging patients, coordinating care, and reporting quality measures. The goals are widespread EHR use and improved healthcare through healthcare IT.
2015 indicator reference guide viral load suppression at 12 months#GOMOJO, INC.
This document provides guidance on the indicator "Percentage of ART patients with a viral load result documented in the medical record within the past 12 months". It aims to monitor the proportion of patients on antiretroviral therapy (ART) who receive routine viral load testing to determine treatment effectiveness. The numerator is the number of ART patients with a documented viral load result in their medical record from the past 12 months. The denominator is the number of ART patients whose medical records were reviewed who have been on treatment for at least 6 months. Achieving high rates of routine viral load testing is important for sustaining treatment outcomes and reducing transmission at scale.
This presentation provides an overview of each Meaningful Use Menu Set Measure as well as its required threshold so that you can learn how to put the Meaningful Use Menu Set Measures into practice.
This document discusses the requirements for Meaningful Use Stage 2. It outlines the core and menu objectives including clinical quality measures, electronic prescribing, health information exchange, patient electronic access, and secure messaging. It provides guidance on exclusions and gives workflows within Practice Fusion for how to meet each objective. Key requirements include reporting 9 clinical quality measures covering 3 domains, using computerized physician order entry for 60% of medications and incorporating structured lab results.
Preparing For A New Era In Health Care Bakersdbuffalogirl
The document discusses the transition to electronic health records mandated by the HITECH Act and ARRA. It defines key terms like EHR, HIE, and meaningful use. It explains that reimbursement will depend on implementing a certified EHR system meeting meaningful use criteria like CPOE, clinical decision support, and information exchange. Point of care testing and laboratories must ensure test results are incorporated into the EHR in structured data. The transition requires reengineering health systems and establishing connectivity between facilities.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Mercurius is named after the roman god mercurius, the god of trade and science. The planet mercurius is named after the same god. Mercurius is sometimes called hydrargyrum, means ‘watery silver’. Its shine and colour are very similar to silver, but mercury is a fluid at room temperatures. The name quick silver is a translation of hydrargyrum, where the word quick describes its tendency to scatter away in all directions.
The droplets have a tendency to conglomerate to one big mass, but on being shaken they fall apart into countless little droplets again. It is used to ignite explosives, like mercury fulminate, the explosive character is one of its general themes.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
2. Overall requirements
EPs must meet or qualify for an exclusion to 17 core objectives and 3
of 5 menu objectives. (Stage 1 was 15/5 of 10)
Eligible hospitals and Critical Access Hospitals must meet or qualify
for an exclusion to 16 core objectives and 2 of 4 menu objectives.
(Stage 1 was 14/5 of 10)
EPs to report 12 CQMs (Stage 1 was 6)
Eligible hospitals and CAHs to report 24 CQMs (Stage 1 was 15)
Alignment with other Quality Measurement initiatives
3. Improving quality, safety, efficiency, and
reducing health disparities
More than 60 percent (Stage 1 was 30%) of medication, laboratory, and
radiology orders created by the EP or authorized providers of the eligible
hospital's or CAH's inpatient or emergency department (POS 21 or 23)
during the EHR reporting period are recorded using CPOE.
More than 65 percent (Stage 1 was 40%) of all permissible prescriptions
written by the EP are compared to at least one drug formulary and
transmitted electronically using Certified EHR Technology.
More than 80 percent (Stage 1 was 50%) of all unique patients seen by the
EP or admitted to the eligible hospital's or CAH's inpatient or emergency
department (POS 21 or 23) have demographics recorded as structured
data.
4. Improving quality, safety, efficiency, and
reducing health disparities
More than 80 percent (Stage 1 was 50%) of all unique patients seen by the
EP or admitted to the eligible hospital's or CAH's inpatient or emergency
department (POS 21 or 23) have blood pressure (for patients age 3 and
over only) and height/length and weight (for all ages) recorded as
structured data
More than 80 percent (Stage 1 was 50%) of all unique patients 13 years old
or older seen by the EP or admitted to the eligible hospital's or CAH's
inpatient or emergency department (POS 21 or 23) have smoking status
recorded as structured data
Implement 5 clinical decision support interventions (Stage 1 was one)
related to 5 or more clinical quality measures at a relevant point in
patient care for the entire EHR reporting period.
The EP, eligible hospital or CAH has enabled and implemented the
functionality for drug-drug and drug- allergy interaction checks for the
entire EHR reporting period. (Stage 1 required implementation)
5. Improving quality, safety, efficiency,
and reducing health disparities
More than 55 percent (Stage 1 was 40%, menu set) of all clinical lab tests results
ordered by the EP or by authorized providers of the eligible hospital or CAH for
patients admitted to its inpatient or emergency department (POS 21 or 23
during the EHR reporting period whose results are either in a positive/negative
or numerical format are incorporated in Certified EHR Technology as structured
data
Generate at least one report listing patients of the EP, eligible hospital or CAH
with a specific condition. (Stage 1 was same)
More than 10 percent of all unique patients who have had an office visit with the
EP within the 24 months prior to the beginning of the EHR reporting period
were sent a reminder, per patient preference (Stage 1 was 20%, menu set)
More than 10 percent of medication orders created by authorized providers of
the eligible hospital's or CAH's inpatient or emergency department (POS 21 or
23) during the EHR reporting period are tracked using eMAR. (New)
6. Engage patients and families in their
health care
More than 50 percent of all unique patients seen by the EP during the EHR reporting
period are provided timely (within 4 business days after the information is available to the
EP) online access to their health information subject to the EP's discretion to withhold
certain information (Stage 1 was 10%, menu set)
More than 10 percent of all unique patients seen by the EP during the EHR reporting
period (or their authorized representatives) view, download , or transmit to a third party
their health information (New)
More than 50 percent of all patients who are discharged from the inpatient or emergency
department (POS 21 or 23) of an eligible hospital or CAH have their information available
online within 36 hours of discharge (Stage 1 was 10%, menu set)
More than 10 percent of all patients who are discharged from the inpatient or emergency
department (POS 21 or 23) of an eligible hospital or CAH view, download or transmit to a
third party their information during the reporting period (New)
7. Engage patients and families
in their health care
Clinical summaries provided to patients within 24 hours for
more than 50 percent of office visits. (Stage 1 was 3 days)
Patient-specific education resources identified by Certified EHR
Technology are provided to patients for more than 10 percent of
all office visits by the EP. More than 10 percent of all unique
patients admitted to the eligible hospital's or CAH's inpatient or
emergency departments (POS 21 or 23) are provided patient-
specific education resources identified by Certified EHR
Technology (Stage 1 was menu set)
A secure message was sent using the electronic messaging
function of Certified EHR Technology by more than 10 percent of
unique patients seen during the EHR reporting period (New)
8. Improve Care Coordination
The EP, eligible hospital or CAH performs medication reconciliation for
more than 65 percent of transitions of care in which the patient is
transitioned into the care of the EP or admitted to the eligible hospital's or
CAH's inpatient or emergency department (POS 21 or 23). (Stage 1 was 50%,
menu set)
The EP, eligible hospital, or CAH that transitions or refers their patient to
another setting of care or provider of care provides a summary of care
record for more than 65 percent of transitions of care and referrals. (Stage 1
was 50%, menu set)
The EP, eligible hospital, or CAH that transitions or refers their patient to
another setting of care or provider of care electronically transmits a
summary of care record using certified EHR technology to a recipient with
no organizational affiliation and using a different Certified EHR Technology
vendor than the sender for more than 10 percent of transitions of care and
referrals. (Stage 1 was one test)
9. Improve Population and Public
Health
Hospital and EP - Successful ongoing submission of electronic
immunization data from Certified EHR Technology to an
immunization registry or immunization information system for the
entire EHR reporting period (Stage 1 was a single test, menu set)
Hospital - Successful ongoing submission of electronic reportable
laboratory results from Certified EHR Technology to public health
agencies for the entire EHR reporting period as authorized. (Stage 1
was a single test, menu set)
Hospital - Successful ongoing submission of electronic syndromic
surveillance data from Certified EHR Technology to a public health
agency for the entire EHR reporting period (Stage 1 was a single test,
menu set)
10. Ensure adequate privacy and security
protections for personal health
information
Conduct or review a security risk analysis in accordance
with the requirements under 45 CFR 164.308(a)(1),
including addressing the encryption/security of data at
rest in accordance with requirements under 45 CFR
164.312 (a)(2)(iv) and 45 CFR 164.306(d)(3), and
implement security updates as necessary and correct
identified security deficiencies as part of the provider's
risk management process. (added data at rest)
11. Menu Set - Improving quality, safety,
efficiency, and reducing health disparities
More than 50 percent of all unique patients 65 years old or older admitted to the
eligible hospital's or CAH's inpatient department (POS 21) during the EHR reporting
period have an indication of an advance directive status recorded as structured data.
(Stage 1 was advance directive indicator only)
More than 40 percent of all scans and tests whose result is an image ordered by the EP
or by an authorized provider of the eligible hospital or CAH for patients admitted to
its inpatient or emergency department (POS 21 and 23) during the EHR reporting
period are accessible through Certified EHR Technology (New)
More than 20 percent of all unique patients seen by the EP or admitted to the eligible
hospital or CAH's inpatient or emergency department (POS 21 or 23) during the EHR
reporting period have a structured data entry for one or more first- degree relatives
(New)
More than 10 percent of hospital discharge medication orders for permissible
prescriptions (for new or changed prescriptions) are compared to at least one drug
formulary and transmitted electronically using Certified EHR Technology (New)
12. Menu Set - Improve Population and
Public Health
EP - Successful ongoing submission of electronic syndromic
surveillance data from Certified EHR Technology to a public health
agency for the entire EHR reporting period (Stage 1 was a single test)
Successful ongoing submission of cancer case information from
Certified EHR Technology to a cancer registry for the entire EHR
reporting period (New)
Successful ongoing submission of specific case information from
Certified EHR Technology to a specialized registry for the entire
EHR reporting period (New)
13. Quality Measures for Eligible
Professionals
Option 1a - EPs would report 12 clinical quality measures from those listed in Table 8, including at least 1 measure from each of
the 6 domains:
Patient and Family Engagement.
Patient Safety.
Care Coordination.
Population and Public Health.
Efficient Use of Healthcare Resources.
Clinical Process/Effectiveness.
Option 1b- EPs would report 11 "core" clinical quality measures listed in Table 6 plus 1 "menu" clinical quality measure from
Table 8.
Option 2: Submit and satisfactorily report clinical quality measures under the Physician Quality Reporting System's EHR
Reporting Option."
Table 6 is based upon analysis of several factors that include: conditions that contribute the most to Medicare and Medicaid
beneficiaries' morbidity and mortality; conditions that represent national public/population health priorities; conditions that
are common to health disparities; those conditions that disproportionately drive healthcare costs that could improve with better
quality measurement; measures that would enable CMS, States, and the provider community to measure quality of care in new
dimensions with a stronger focus on parsimonious measurement; and those measures that include patient and/or caregiver
engagement.
Table 8 lists all of the clinical quality measures that we are considering for EPs to report for the EHR Incentive Programs
beginning with CY 2014.
14. Quality Measures for Hospitals
Requires eligible hospitals and CAHs to report 24 clinical quality measures
from a menu of 49 clinical quality measures, including at least 1 clinical quality
measure from each of the 6 domains:
Clinical Process/Effectiveness.
Patient Safety.
Care Coordination.
Efficient Use of Healthcare Resources
Patient & Family Engagement.
Population & Public Health.
The measures in Table 9 are based on statutory requirements, the HITPC's
recommendations, alignment with other CMS and national hospital quality
measurement programs such as the Joint Commission, the Medicare Hospital
Inpatient Quality Reporting Program and Hospital Value-Based Purchasing
Program, and the National Quality Strategy.